Abstract
Somatic mutations in cancer genes have been detected in clonal expansions across healthy human tissue, including in clonal hematopoiesis. However, because mutated and wild-type cells are admixed, we have limited ability to link genotypes with phenotypes. To overcome this limitation, we leveraged multi-modality single-cell sequencing, capturing genotype, transcriptomes and methylomes in progenitors from individuals with DNMT3A R882 mutated clonal hematopoiesis. DNMT3A mutations result in myeloid over lymphoid bias, and an expansion of immature myeloid progenitors primed toward megakaryocytic–erythroid fate, with dysregulated expression of lineage and leukemia stem cell markers. Mutated DNMT3A leads to preferential hypomethylation of polycomb repressive complex 2 targets and a specific CpG flanking motif. Notably, the hypomethylation motif is enriched in binding motifs of key hematopoietic transcription factors, serving as a potential mechanistic link between DNMT3A mutations and aberrant transcriptional phenotypes. Thus, single-cell multi-omics paves the road to defining the downstream consequences of mutations that drive clonal mosaicism.
Original language | English (US) |
---|---|
Pages (from-to) | 1514-1526 |
Number of pages | 13 |
Journal | Nature Genetics |
Volume | 54 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2022 |
Funding
The work was enabled by the Weill Cornell Epigenomics Core and Flow Cytometry Core. We thank A. Melnick (Weill Cornell Medicine) for a critical review of the manuscript. A.S.N. is supported by the Burroughs Wellcome Fund Career Award for Medical Scientists, the National Institutes of Health Director\u2019s Early Independence Award (DP5 OD029619) and the Starr Cancer Consortium. N.D. is supported by a F30 Predoctoral Fellowship from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (F30HL156496). N.D. and R.M.M. are supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health under award number T32GM007739 to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program. F.I. is supported by the American Society of Hematology Fellow-to-Faculty Scholar Award. R.C. is supported by Lymphoma Research Foundation and Marie Sk\u0142odowska-Curie fellowships. I.G. is supported by a grant from the Dr Miriam and Sheldon G. Adelson Medical Research Foundation, and a Stand Up To Cancer Dream Team Research Grant (SU2C-AACR-DT-28-18). D.A.L. is supported by the Burroughs Wellcome Fund Career Award for Medical Scientists, Valle Scholar Award, the National Institutes of Health Director\u2019s New Innovator Award (DP2-CA239065), the Chan Zuckerberg Initiative Award, the Leukemia Lymphoma Society Career Development Program Award and the Mark Foundation Emerging Leader Award. This work was also supported by the NHLBI (R01HL145283) and the National Human Genome Research Institute, Center of Excellence in Genomic Science (RM1HG011014).
ASJC Scopus subject areas
- Genetics